Development of Treatment Options for Chinese Patients with Advanced Squamous Cell Lung Cancer: Focus on Afatinib

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Mar 14

PMID 30863118

Citations 3

Authors

Shun Lu

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer death in China, and approximately one third of these cancers are squamous cell carcinoma (SqCC) of the lung. Ethnic diversity and country-specific environmental factors can account for interindividual variations in response to and tolerability of anticancer therapies. Although several targeted therapies have recently been approved for patients with relapsed/refractory SqCC of the lung, only afatinib, an irreversible ErbB family blocker, has data of Chinese patients. In the Phase III LUX-Lung 8 trial, afatinib demonstrated a significant clinical benefit vs the reversible first-generation EGFR tyrosine kinase inhibitor erlotinib in both the overall population and the Chinese subset, with a manageable safety profile. Emerging biomarker data from LUX-Lung 8 suggest that patients with ErbB mutations, especially ErbB2, and those classified as "good" in the VeriStrat proteomic test, may benefit from afatinib treatment in particular, regardless of ethnicity, and may get a long-term response. In conclusion, afatinib is a valid second-line option for Chinese patients with SqCC of the lung, and specific biomarkers may help guide in treatment decision-making. Ongoing studies will provide further guidance on afatinib's place in the treatment algorithm, alongside the other novel targeted therapies.

Citing Articles

Prognostic Indicators for Precision Treatment of Non-Small Cell Lung Carcinoma.

Ghosh D, McDonald H, Dutta R, Krishnan K, Thilakan J, Paul M Cells. 2024; 13(21.

PMID: 39513892 PMC: 11545304. DOI: 10.3390/cells13211785.

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management.

Sutic M, Vukic A, Baranasic J, Forsti A, Dzubur F, Samarzija M J Pers Med. 2021; 11(11).

PMID: 34834454 PMC: 8624402. DOI: 10.3390/jpm11111102.

A prognostic model for elderly patients with squamous non-small cell lung cancer: a population-based study.

Chen S, Gao C, Du Q, Tang L, You H, Dong Y J Transl Med. 2020; 18(1):436.

PMID: 33198777 PMC: 7670679. DOI: 10.1186/s12967-020-02606-3.

References

Giovino G . Epidemiology of tobacco use in the United States. Oncogene. 2002; 21(48):7326-40. DOI: 10.1038/sj.onc.1205808. View

Hirsch F, Varella-Garcia M, Bunn Jr P, Di Maria M, Veve R, Bremmes R . Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003; 21(20):3798-807. DOI: 10.1200/JCO.2003.11.069. View

Heinmoller P, Gross C, Beyser K, Schmidtgen C, Maass G, Pedrocchi M . HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clin Cancer Res. 2003; 9(14):5238-43. View

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

Ugocsai K, Mandoky L, Tiszlavicz L, Molnar J . Investigation of HER2 overexpression in non-small cell lung cancer. Anticancer Res. 2005; 25(4):3061-6. View

Clark G, Zborowski D, Santabarbara P, Ding K, Whitehead M, Seymour L . Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer. 2006; 7(6):389-94. DOI: 10.3816/clc.2006.n.022. View

Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K . Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007; 99(11):838-46. DOI: 10.1093/jnci/djk195. View

Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac L . BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008; 27(34):4702-11. PMC: 2748240. DOI: 10.1038/onc.2008.109. View

Molina J, Yang P, Cassivi S, Schild S, Adjei A . Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83(5):584-94. PMC: 2718421. DOI: 10.4065/83.5.584. View

10.

Sekine I, Yamamoto N, Nishio K, Saijo N . Emerging ethnic differences in lung cancer therapy. Br J Cancer. 2008; 99(11):1757-62. PMC: 2600690. DOI: 10.1038/sj.bjc.6604721. View

11.

ODonnell P, Dolan M . Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009; 15(15):4806-14. PMC: 2774468. DOI: 10.1158/1078-0432.CCR-09-0344. View

12.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

13.

Lee H, Xu X, Choe G, Chung D, Seo J, Lee J . Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer. 2009; 68(3):375-82. DOI: 10.1016/j.lungcan.2009.07.014. View

14.

Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J . Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2009; 11(2):121-8. DOI: 10.1016/S1470-2045(09)70364-X. View

15.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H . Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362(25):2380-8. DOI: 10.1056/NEJMoa0909530. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Li Q, Hsia J, Yang G . Prevalence of smoking in China in 2010. N Engl J Med. 2011; 364(25):2469-70. DOI: 10.1056/NEJMc1102459. View

18.

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X. View

19.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

20.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View